UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Lowers Holdings in Inspire Medical Systems, Inc. (NYSE:INSP)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its position in Inspire Medical Systems, Inc. (NYSE:INSP) by 35.6% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 365,168 shares of the company’s stock after selling 201,508 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 1.22% of Inspire Medical Systems worth $77,069,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of the company. Public Sector Pension Investment Board acquired a new position in shares of Inspire Medical Systems during the third quarter worth about $13,359,000. BNP Paribas Financial Markets boosted its holdings in Inspire Medical Systems by 99.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 4,711 shares of the company’s stock valued at $994,000 after purchasing an additional 2,352 shares in the last quarter. Algert Global LLC increased its position in Inspire Medical Systems by 145.1% during the 3rd quarter. Algert Global LLC now owns 45,563 shares of the company’s stock worth $9,616,000 after purchasing an additional 26,971 shares during the period. Cerity Partners LLC raised its stake in shares of Inspire Medical Systems by 409.2% during the 3rd quarter. Cerity Partners LLC now owns 13,576 shares of the company’s stock worth $2,865,000 after buying an additional 10,910 shares in the last quarter. Finally, Eagle Asset Management Inc. lifted its holdings in shares of Inspire Medical Systems by 82.4% in the 3rd quarter. Eagle Asset Management Inc. now owns 260,753 shares of the company’s stock valued at $51,269,000 after buying an additional 117,819 shares during the period. Hedge funds and other institutional investors own 94.91% of the company’s stock.

Inspire Medical Systems Price Performance

Shares of Inspire Medical Systems stock opened at $188.70 on Tuesday. Inspire Medical Systems, Inc. has a 1 year low of $123.00 and a 1 year high of $257.40. The business has a 50 day moving average price of $197.40 and a 200 day moving average price of $176.66. The company has a market capitalization of $5.66 billion, a P/E ratio of 176.36 and a beta of 1.36.

Inspire Medical Systems (NYSE:INSP) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.54. Inspire Medical Systems had a return on equity of 5.30% and a net margin of 4.37%. The business had revenue of $203.20 million for the quarter, compared to analyst estimates of $197.59 million. During the same quarter last year, the company earned ($0.29) earnings per share. The business’s revenue for the quarter was up 32.6% compared to the same quarter last year. As a group, research analysts expect that Inspire Medical Systems, Inc. will post 1.33 EPS for the current fiscal year.

Insider Transactions at Inspire Medical Systems

In other news, Director Shawn Mccormick sold 800 shares of Inspire Medical Systems stock in a transaction on Monday, September 9th. The stock was sold at an average price of $220.00, for a total value of $176,000.00. Following the completion of the sale, the director now owns 23,140 shares of the company’s stock, valued at $5,090,800. The trade was a 3.34 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 4.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Leerink Partners upped their price objective on Inspire Medical Systems from $167.00 to $197.00 and gave the stock a “market perform” rating in a report on Tuesday, September 10th. Bank of America upgraded shares of Inspire Medical Systems from a “neutral” rating to a “buy” rating and increased their price target for the company from $220.00 to $255.00 in a report on Wednesday, November 20th. Piper Sandler reiterated an “overweight” rating and issued a $260.00 price objective (up previously from $255.00) on shares of Inspire Medical Systems in a research note on Tuesday, November 5th. Wells Fargo & Company upped their target price on shares of Inspire Medical Systems from $187.00 to $198.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th. Finally, Robert W. Baird lifted their price target on shares of Inspire Medical Systems from $240.00 to $252.00 and gave the company an “outperform” rating in a research report on Tuesday, November 5th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $233.58.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.